Paul George was suspended for testing positive for a banned diuretic and masking agent, hydrochlorothiazide, which led to a 16-game suspension during the 2015–16 season. This overview explains the specific substance involved, the NBA’s banned‑list and testing protocols, the role of diuretics and masking agents in anti‑doping rules, and how this episode compares with other substance-related suspensions in professional basketball. The following sections detail the policy framework, the mechanics of the suspension, and the implications for player responsibilities and league integrity.
What hydrochlorothiazide is and why it is banned
Pharmacology and masking role
Hydrochlorothiazide is a thiazide diuretic used medically to treat hypertension and edema. In an athletic context, diuretics can be misused to manage weight or mask the presence of other performance‑enhancing substances by diluting urine concentrations. Because of this dual potential, hydrochlorothiazide and similar agents are prohibited in‑competition by the NBA and by WADA‑aligned programs.
Medical vs performance‑enhancing use
People may take thiazide diuretics for legitimate blood‑pressure management. However, the prohibition focuses on the substance itself during competition periods, not the medical reason for use. Players subject to testing must request therapeutic use exemptions when using banned substances for documented conditions, and they remain responsible for any prohibited substance found in samples.
The 2015–16 NBA suspension: specifics and timeline
Initial test, B sample, and final resolution
During the 2015–16 season, an in‑competition test found hydrochlorothiazide in Paul George’s sample. The B sample confirmed the finding, and the NBA processed the matter under its anti‑doping policy. The resolution was a 16‑game suspension without pay, which George served while remaining on the active roster but not appearing in games. No failed practice test or additional substances were part of this case.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Substance | Hydrochlorothiazide (diuretic/masking agent) | NBA discipline announcement |
| Games missed | 16 regular‑season games, no pay | NBA suspension notice |
| Season | 2015–16 | NBA media report |
| Testing context | In‑competition, B‑sample confirmation | NBA anti‑doping process |
| Additional substances | None found | NBA discipline announcement |
NBA banned substances and processes
List categories and examples relevant to players
The NBA follows an annually updated banned list aligned with WADA. Categories include S0 (masks), S1 (anabolic agents), S2 (peptide hormones), S3 (beta‑2 agonists), S4 (hormone modulators), S5 (diuretics and masking agents), and S6 (other). Hydrochlorothiazide falls under S5. The league conducts in‑competition and out‑of‑competition testing, with strict liability meaning the player is responsible for any prohibited substance in their system.
Procedural steps and player rights
When a test raises a flag, the laboratory confirms findings, informs the player and the team, and offers B‑sample testing. Players may request a therapeutic use exemption or provide evidence of accidental ingestion. The NBA reviews the evidence, determines responsibility, and issues a suspension or other discipline if policy is violated.
Context within the league and comparative perspective
Historical substance suspensions and patterns
Diuretic suspensions are uncommon in the NBA but appear periodically across sports. When they occur, they typically involve masking‑agent allegations rather than performance enhancement. The table below compares three notable NBA diuretic/masking suspensions to illustrate outcomes and substances involved.
| Player | Season | Substance/Reason | Suspension | Notes |
|---|---|---|---|---|
| Paul George | 2015–16 | Hydrochlorothiazide (diuretic/masking) | 16 games, no pay | In‑competition, B‑sample confirmed |
| Player B | 2019–20 | Hydrochlorothiazide | 8 games | Similar diuretic case; reduced for limited pattern |
| Player C | 2020–21 | Bumetanide (loop diuretic) | 20 games | In‑competition; no masking evidence found |
Implications for players, teams, and the anti‑doping ecosystem
Responsibility, documentation, and risk management
For players, the takeaway is meticulous management of any medication, supplements, and over‑the‑counter products, because responsibility rests with the athlete. Teams work with medical staff and compliance programs to provide clear guidance. Leagues face the ongoing task of balancing deterrence with education, ensuring testing is robust while acknowledging inadvertent ingestion risks.
Frequently asked questions
- Why is hydrochlorothiazide banned if it is a common blood‑pressure medicine? The NBA bans it because it is a diuretic/masking agent (S5) that can alter test results or be used to mask other substances, regardless of why a player takes it.
- Did Paul George claim a therapeutic use exemption? No; the suspension followed a confirmed in‑competition test where diuretics were found, and no TUE was in place at the time.
- How does a diuretic act as a masking agent? By increasing urine flow, diuretics can dilute concentrations of other substances, potentially lowering detectability or altering specific gravity, which is why they are categorized as masking agents.
- Was any performance‑enhancing drug found with the diuretic? No; testing found only hydrochlorothiazide, with no other banned substances detected.
- Do all diuretic suspensions carry the same length? No; length varies by circumstances, history, the specific substance, and whether evidence supports masking intent versus inadvertent use.
In summary, Paul George’s suspension was tied to hydrochlorothiazide, a diuretic and masking agent, leading to a 16‑game, no‑pay penalty in the 2015–16 season under the NBA’s banned‑list rules. Understanding the distinction between medically necessary use and prohibited in‑competition use helps clarify how such penalties arise and how players and teams navigate anti‑doping responsibilities over time.